Impact of a community pharmacists' hypertension-care service on medication adherence. The AFenPA study

Research in Social and Administrative Pharmacy

Volumn 9, Issue 6, 2013, Pages 797-805

  Fikri Benbrahim, Narjis ^a   Faus, María José ^a   Martínez Martínez, Fernando ^a   Sabater Hernández, Daniel ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

Community pharmacies; Hypertension; Medication adherence; Pharmacist intervention; Spain

Indexed keywords

ANTIHYPERTENSIVE AGENT;

AGED; ARTICLE; COMMUNITY PHARMACIES; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PHARMACIST; PHARMACIST INTERVENTION; PHARMACY; PROFESSIONAL STANDARD; PROGRAM EVALUATION; SPAIN;

COMMUNITY PHARMACIES; HYPERTENSION; MEDICATION ADHERENCE; PHARMACIST INTERVENTION; SPAIN;

AGED; ANTIHYPERTENSIVE AGENTS; COMMUNITY PHARMACY SERVICES; FEMALE; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHARMACISTS; PROFESSIONAL ROLE; PROGRAM EVALUATION;

EID: 84887606123     PISSN: 15517411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sapharm.2012.12.006     Document Type: Article

References (46)

1. Rodgers A., Vaughan P., Prentice T., Edejer T.-T., Evans D. The World Health Report 2002 2002, WHO.
2. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913. Prospective Studies Collaboration.
3. Graciani A., Zuluaga-Zuluaga M.C., Banegas J.R., Leon-Munoz L.M., de la Cruz J.J., Rodriguez-Artalejo F. [Cardiovascular mortality attributable to high blood pressure in Spanish population over 50]. Med Clin (Barc) 2008, 131:125-129.
4. Collins R., MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994, 50:272-298.
5. Barrios V., Banegas J.R., Ruilope L.M., Rodicio J.L. Evolution of blood pressure control in Spain. JHypertens 2007, 25:1975-1977.
6. Llisterri J.L., Rodríguez-Roca G.C., Alonso F.J., et al. [Control of blood pressure in Spanish hypertensive population attended in primary health-care. PRESCAP 2006 Study]. Med Clin (Barc) 2008, 130:681-687.
7. Schroeder K., Fahey T., Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev 2004, CD004804.
8. World Health Organization Adherence to Long Term Therapies: Evidence for Action 2003, WHO, Geneva.
9. Dowell J., Jones A., Snadden D. Exploring medication use to seek concordance with 'non-adherent' patients: a qualitative study. Br J Gen Pract 2002, 52:24-32.
10. Hepler C.D., Strand L.M. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990, 47:533-543.
11. Morgado M.P., Morgado S.R., Mendes L.C., Pereira L.J., Castelo-Branco M. Pharmacist interventions to enhance blood pressure control and adherence to antihypertensive therapy: review and meta-analysis. Am J Health Syst Pharm 2011, 68:241-253.
12. Machado M., Bajcar J., Guzzo G.C., Einarson T.R. Sensitivity of patient outcomes to pharmacist interventions. Part II: systematic review and meta-analysis in hypertension management. Ann Pharmacother 2007, 41:1770-1781.
13. Aguwa C.N., Ukwe C.V., Ekwunife O.I. Effect of pharmaceutical care programme on blood pressure and quality of life in a Nigerian pharmacy. Pharm World Sci 2008, 30:107-110.
14. Blenkinsopp A., Phelan M., Bourne J., Dakhik N. Extended adherence support by community pharmacists for patients with hypertension: a randomized controlled trial. Int J Pharm Pract 2000, 8:165-175.
15. Chabot I., Moisan J., Gregoire J.P., Milot A. Pharmacist intervention program for control of hypertension. Ann Pharmacother 2003, 37:1186-1193.
16. Sookaneknun P., Richards R.M., Sanguansermsri J., Teerasut C. Pharmacist involvement in primary care improves hypertensive patient clinical outcomes. Ann Pharmacother 2004, 38(12):2023-2028.
17. Robinson J.D., Segal R., Lopez L.M., Doty R.E. Impact of a pharmaceutical care intervention on blood pressure control in a chain pharmacy practice. Ann Pharmacother 2010, 44:88-96.
18. Lee J.K., Grace K.A., Taylor A.J. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006, 296:2563-2571.
19. Lai L.L. Community pharmacy-based hypertension disease-management program in a Latino/Hispanic-American population. Consult Pharm 2007, 22:411-416.
20. Gil V., Pineda M., Martinez J.L., Belda J., Santos M.L., Merino J. [Validity of 6 indirect methods to assess treatment compliance in arterial hypertension]. Med Clin (Barc) 1994, 102:532-536.
21. Prado J.C., Kupek E., Mion D. Validity of four indirect methods to measure adherence in primary care hypertensives. J Hum Hypertens 2007, 21:579-584.
22. Fikri-Benbrahim N., García-Cárdenas V., Sáez-Benito L., Gastelurrutia M.A., Faus M.J. Adherence: a review of education, research, practice and policy in Spain. Pharm Pract 2009, 7:125-138.
23. Torres A., Fité B., Gascón P., et al. [Effectiveness of a pharmaceutical care program in the improvement of blood pressure monitoring in poorly controlled hypertensive patients. PressFarm Study]. Hipertens riesgo vasc 2010, 27:13-22.
24. Chamorro M.A., García-Jiménez E., Amariles P., et al. [Effect of pharmacist involvement in adherence to medications in patients with high to moderate cardiovascular risk (study EMDADER-CV-INCUMPLIMIENTO)]. Aten Primaria 2011, 43:245-253.
25. Arias J.L., Santamaría-López J.M. [Improvement of the drug therapy results in patients with high blood pressure at a community pharmacy]. Ars Pharm 2008, 49:13-24.
26. Llaves García E., Segura Beltrán M.M., García-Jiménez E., Baena Parejo I. [Personalized medication dosage systems for treatment compliance in patients with hypertension and dyslipidaemia]. Aten Primaria 2009, 41:472-473.
27. Fikri-Benbrahim N., Faus M.J., Martínez-Martínez F., González-Segura Alsina D., Sabater-Hernández D. Effect of a pharmacist intervention in Spanish community pharmacies on blood pressure control in hypertensive patients. The AFenPA study. Am J Health Syst Pharm 2012, 18:311-323.
28. Fikri-Benbrahim N., Sabater-Hernández D., Fikri-Benbrahim O., Faus M., Martínez-Martínez F., González-Segura Alsina D. Effect of pharmaceutical intervention on medication adherence and blood pressure control in treated hypertensive patients: rationale, design and methods of the AFenPA pilot study. Ars Pharm 2011, 52:29-38.
29. Bueno Gomez M., Barrionuevo Sancho M.D., Fikri Benbrahim N., Garcia-Jimenez E. [Causes of non-compliance of patients who attend a community pharmacy in Granada]. Aten Primaria 2008, 40:105-106.
30. Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986, 24:67-74.
31. Batalla Martínez C., Blanquer A., Ciurana R., et al. Cumplimiento de la prescripción farmacológica enpacientes hipertensos. Aten Primaria 1986, 3:21-24.
32. de la Sierra A., Gorostidi M., Marin R., et al. Evaluation and management of hypertension in Spain. A consensus guide. Med Clin (Barc) 2008, 131:104-116.
33. Pineiro F., Gil V., Donis M., Orozco D., Pastor R., Merino J. [The validity of 6 indirect methods for assessing drug treatment compliance in arterial hypertension]. Aten Primaria 1997, 19:372-374. 376.
34. Osterberg L., Blaschke T. Adherence to medication. N Engl J Med 2005, 353:487-497.
35. van Onzenoort H.A., Verberk W.J., Kessels A.G., et al. Assessing medication adherence simultaneously by electronic monitoring and pill count in patients with mild-to-moderate hypertension. Am J Hypertens 2010, 23:149-154.
36. Márquez C.E., Gutiérrez M.C., Jiménez J.C., Franco R.C., Baquero S.C., Ruiz B.R. [Therapeutic observance in arterial hypertension. Reliability of indirect methods assessing therapeutic compliance]. Aten Primaria 1995, 16:496-500.
37. Marquez Contreras E., Vegazo Garcia O., Claros N.M., et al. [Efficacy of telephone and mailintervention in patient compliance with antihypertensive drugs in hypertension. ETECUM-HTA study]. Blood Press 2005, 14:151-158.
38. Prado-Aguilar C.A., Martinez Y.V., Segovia-Bernal Y., Reyes-Martinez R., Arias-Ulloa R. Performance of two questionnaires to measure treatment adherence in patients with Type-2 diabetes. BMC Public Health 2009, 9:38.
39. Haynes R.B., Taylor D.W., Sackett D.L., Gibson E.S., Bernholz C.D., Mukherjee J. Can simple clinical measurements detect patient noncompliance?. Hypertension 1980, 2:757-764.
40. de Souza W.A., Yugar-Toledo J.C., Bergsten-Mendes G., Sabha M., Moreno H. Effect of pharmaceutical care on blood pressure control and health-related quality of life in patients with resistant hypertension. Am J Health Syst Pharm 2007, 64:1955-1961.
41. Von Muenster S.J., Carter B.L., Weber C.A., et al. Description of pharmacist interventions during physician-pharmacist co-management of hypertension. Pharm World Sci 2008, 30:128-135.
42. Sabater-Hernández D., de la Sierra A., Bellver-Monzó O., et al. [Action guide for community pharmacist in patients with hypertension and cardiovascular risk. Consensus document (condensed version)]. Ars Pharm 2011, 52:38-58.
43. Ogedegbe G., Schoenthaler A. A systematic review of the effects of home blood pressure monitoring on medication adherence. J Clin Hypertens (Greenwich) 2006, 8:174-180.
44. Morgado M., Rolo S., Castelo-Branco M. Pharmacist intervention program to enhance hypertension control: a randomised controlled trial. Int J Clin Pharm 2011, 33:132-140.
45. Obreli-Neto P.R., Guidoni C.M., de Oliveira Baldoni A., et al. Effect of a 36-month pharmaceutical care program on pharmacotherapy adherence in elderly diabetic and hypertensive patients. Int J Clin Pharm 2011, 33:642-649.
46. Jimmy B., Jose J. Patient medication adherence: measures in daily practice. Oman Med J 2011, 26:155-159.